KRAS and non-small cell lung carcinoma: A phase II trial comparing single agent selumetinib (AZD6244 or ARRY-142886) versus pemetrexed in previously treated patients with advanced NSCLC and unreported KRAS status showed no significant clinical benefit in terms of RR or median PFS [107].